

POLICY: 554.44
TITLE: Pain Management

EFFECTIVE: 9/1/2026
REVIEW: 8/2028
SUPERCEDES:

APPROVAL SIGNATURES ON FILE IN EMS OFFICE

PAGE: 1 of 2

PAIN MANAGEMENT

- I. AUTHORITY
Health and Safety Code, Division 2.5, California Code of Regulations, Title 22, Division 9
- II. PURPOSE
To serve as a patient treatment standard for EMRs, EMTs, AEMTs, and Paramedics within their scope of practice.
- III. PROTOCOL
Pain control can reduce the patient's anxiety and discomfort, thereby improving the patient's comfort and ability to cooperate. The patient's severity of pain must be properly assessed in order to provide appropriate relief. This protocol is not intended to totally alleviate pain, but to safely decrease the intensity of the pain without causing physiologic compromise, delaying transport to definitive care, or interfering with the patient's diagnostic work-up.

**Provider Key: F = First Responder/EMR E = EMT O = EMT Local Optional SOP
P = Paramedic A=Advanced EMT D = Base Hospital Physician Order Required**

	F	E	O	A	P	D
ASSESSMENT: including pain scale.	X	X	X	X	X	
PULSE OXIMETRY: consider if administering sedating medication.		X	X	X	X	
CAPNOGRAPHY: consider if administering sedating medication.					X	
OXYGEN: if pulse oximetry <94% or signs of respiratory distress or hypoperfusion.	X	X	X	X	X	
PAIN TREATMENT (NON-CARDIAC): consider non-pharmaceutical options: position of comfort, splint, ice, elevate as indicated.	X	X	X	X	X	
ECG MONITOR: lead placement may be delegated. Treat as indicated.					X	
VASCULAR ACCESS: P - IV/IO, AEMT - IV only, rate as indicated.				X	X	
PHARMACEUTICAL PAIN TREATMENT: Choose most appropriate pharmaceutical intervention below. Non-opioid interventions should be considered first.					X	
ACETAMINOPHEN: 15 mg/kg, oral suspension or IV infusion. Administer IV infusion over 15 minutes. Total max dose 1000 mg. No repeat dose. Do not use if severe hepatic impairment, active liver disease, or allergy.					X	
KETOROLAC: For abdominal, back or extremity pain, 15 mg, IN/IM/IV/IO. Ketorolac is not to be used in patients under 2 or over 65.					X	

	F	E	O	P	D
†FENTANYL: 1-2 mcg/kg, maximum of 3 mcg/kg, IV/IO/IM/IN. If initial dose given IV/IO/IN, may repeat in 5 minutes, or if initial dose given IM may repeat in 10 minutes. Repeat doses at 0.5 mcg/kg. Use for moderate pain (score 4-6) or severe pain (score 7-10). Fentanyl is to be used with caution in patients taking narcotics, benzodiazepines, MAOIs, <u>conivaptan</u>, <u>crizotinib</u>, <u>linezolid</u>, <u>nalbuphine</u>, <u>pazopanib</u>, <u>pentazocine</u>, <u>sibutramine</u>, <u>sodium oxalate</u>, <u>rifampin/ isoniazid</u>.				X	
*MORPHINE: Titrate in 2 – 5 mg increments IV/IO every 3 – 5 minutes (if systolic BP > 90 mmHg). If no IV/IO available, 5 – 10 mg IM, which may be repeated in 20 minutes. Maximum total dose 30 mg.				X	
KETAMINE: Mix 0.3 mg/kg (max. 30 mg) in 50 – 100 mL normal saline or D5W and label bag. Administer <u>slowly</u> over five (5) minutes. Place “KETAMINE ADMINISTERED” band on patient’s wrist. May repeat for severe pain fifteen (15) minutes after medication infusion finishes.				X	
MIDAZOLAM: 0.5 – 1 mg increments titrated to patient’s pain or spasm up to 5 mg IV/IO/IN. If no IV access available, 2 – 10 mg IM, 10 mg maximum.				X	
BASE CONTACT: for additional dosing guidance if indicated.					X

USE WITH CAUTION IN PATIENTS WITH

- Head trauma* †
- Altered mental status* †
- ETOH intoxication* †
- Decreased respirations*†
- Blood pressures < 90mmhg systolic*
- Elderly patients* †

AVOID THE USE OF MORPHINE AND FENTANYL CONCURRENTLY: If a patient experiences an adverse effect from one of these medications, the patient is experiencing unrelenting severe pain, and the transport time is extended, changing to the alternate medication may be appropriate with Base Hospital Physician consultation.